EP0325199A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Fumagillin as angiostatic agent
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1989-01-17
•
Granted: —
•
Expires: 2009-01-17
Abstract
Abstract Fumagillin and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization. The invention also provides certain pharmaceutical compositions comprising fumagillin or its salt, and an agent which potentiates angiogenesis inhibition such as heparin and sulfated cyclodextrins such as beta-cyclodextrin tetradecasulfate.
Inventors
- 👤 Judah Folkman
- 👤 Donald Ingber
- 👤 Takeshi Fujita
- 👤 Tsuneo Kanamaru
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 15:16
CPC Classifications
B; B82; B82Y; B82Y5/00; A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/56; A61K31/57; A61K47/00; A61K47/50; A61K47/69; A61K47/6949; A61K47/6951; A61L; A61L27/00; A61L27/50; A61L27/54; A61P; A61P9/00; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/50; C07K14/503; C08; C08B; C08B37/00; C08B37/0006; C08B37/0009; C08B37/0012; A61K38/00; A61L2300/00; A61L2300/20; A61L2300/23; A61L2300/236; A61L2300/40; A61L2300/416; A61L2300/80; A61L2300/802
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
21 words
Use of fumagillin or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treating or preventing of angiogenesis.
Claim 2
Dependent Claim
21 words
Use of fumagillin or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treating or preventing of angiogenesis.
Claim 3
Dependent Claim
30 words
Use of fumagillin or a pharmaceutically acceptable salt thereof in conjunction with an agent which potentiates angiogenesis inhibition for preparing a pharmaceutical composition for the treating or preventing of angiogenesis.
Claim 4
Dependent Claim
30 words
Use of fumagillin or a pharmaceutically acceptable salt thereof in conjunction with an agent which potentiates angiogenesis inhibition for preparing a pharmaceutical composition for the treating or preventing of angiogenesis.
Claim 5
Dependent Claim
23 words
Use according to claim 2 wherein the agent which potentiates angiogenesis inhibition is selected from the group of heparin and beta cyclodextrin tetradecasulfate.
Claim 6
Dependent Claim
25 words
A pharmaceutical composition for the treatment of angiogenesis in mammals comprising fumagillin or a pharmaceutically acceptable salt thereof and an agent which potentiates angiogenesis inhibition.
Claim 7
Dependent Claim
25 words
A pharmaceutical composition for the treatment of angiogenesis in mammals comprising fumagillin or a pharmaceutically acceptable salt thereof and an agent which potentiates angiogenesis inhibition.
Claim 8
Dependent Claim
24 words
The pharmaceutical composition of claim 4, wherein the agent which potentiates angiogenesis inhibition is selected from the group of heparin and beta cyclodextrin tetradecasulfate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.